Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
- Conditions
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Julia Brown
- Target Recruit Count
- 122
- Registration Number
- NCT01295151
- Locations
- 🇬🇧
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom
Abatacept in the Treatment of Uveitis
- First Posted Date
- 2011-01-20
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 10
- Registration Number
- NCT01279954
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Study on the Safety of Abatacept in Relapsing Polychondritis
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 4
- Registration Number
- NCT01272856
- Locations
- 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01221636
- Locations
- 🇺🇸
Local Institution, Austin, Texas, United States
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 511
- Registration Number
- NCT01142726
- Locations
- 🇺🇸
Johns Hopkins University Division Of Rheumatology, Baltimore, Maryland, United States
🇺🇸Physician Research Collaboration, Llc, Lincoln, Nebraska, United States
🇺🇸Rheumatology Associates Of North Alabama, P.C., Huntsville, Alabama, United States
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
- Conditions
- AMLALLUndifferentiated LeukemiaBiphenotypic LeukemiaRefractory AnemiaRefractory Anemia With Ringed SideroblastsRefractory Cytopenia With Multilineage DysplasiaRef. Cytopenia w Multilineage Dysplasia & Ringed SideroblastsRefractory Anemia With Excess Blasts-1 (5-10% Blasts)Refractory Anemia With Excess Blasts-2 (10-20% Blasts)
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT01012492
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2011-06-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 108
- Registration Number
- NCT00989235
Abatacept Versus Adalimumab Head-to-Head
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 869
- Registration Number
- NCT00929864
- Locations
- 🇺🇸
Laureate Clinical Research Group, Atlanta, Georgia, United States
🇺🇸Mountain State Clinical Research, Clarksburg, West Virginia, United States
🇺🇸Arthritis And Rheumatic Disease Specialties, Aventura, Florida, United States
The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2014-02-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT00784459
- Locations
- 🇺🇸
Washington University School of Medicine, saint Louis, Missouri, United States
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2016-02-08
- Target Recruit Count
- 137
- Registration Number
- NCT00774852
- Locations
- 🇺🇸
Feinstein Institute, Manhasset, New York, United States
🇺🇸UT Southwestern, Dallas, Texas, United States
🇺🇸University of Alabama, Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.